Reports of Radiotherapy and Oncology

Published by: Kowsar

Evaluation of Correlation Between Serum Level of Dihydropyrimidine Dehydrogenase Enzyme and Capecitabine Induced Adverse Reaction

Abolghasem Allahyari 1 , Maryam Sheikhvanloo 2 , Mahdi Jannati 2 , Fatemeh Kalalinia 3 , Amir Hoooshang Mohamadpoor 2 , 4 and Sepideh Elyasi 2 , *
Authors Information
1 Hematology-Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
3 Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
4 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Reports of Radiotherapy and Oncology: June 2017, 4 (1); e80910
  • Published Online: August 14, 2018
  • Article Type: Research Article
  • Received: June 16, 2018
  • Revised: July 21, 2018
  • Accepted: August 6, 2018
  • DOI: 10.5812/rro.80910

To Cite: Allahyari A, Sheikhvanloo M, Jannati M, Kalalinia F, Mohamadpoor A H, et al. Evaluation of Correlation Between Serum Level of Dihydropyrimidine Dehydrogenase Enzyme and Capecitabine Induced Adverse Reaction, Rep Radiother Oncol. 2017 ; 4(1):e80910. doi: 10.5812/rro.80910.

Abstract
Copyright © 2018, Reports of Radiotherapy and Oncology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Baan J, Bos MMEM, Gonesh-Kisoensingh SU, Meynaar IA, Alsma J, Meijer E, et al. Capecitabine-induced toxicity: an outcome study into drug safety. J Integr Oncology. 2014;3(1). doi: 10.4172/2329-6771.1000113.
  • 2. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. [PubMed: 15763604].
  • 3. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-88. doi: 10.1016/s1470-2045(12)70116-x.
  • 4. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-904. doi: 10.1158/1535-7163.MCT-06-0327. [PubMed: 17121937].
  • 5. Salek R, Hosseini BA, Behravan J, Aledavood A, Sadeghi Ivari M. A survey on the prevalence of IVS14 + 1G > a mutation of the dihydropyrimidine dehydrogenase gene among a group of colorectal cancer patients in northeast iran, the relevance of fluoropyrimidine based chemotherapy toxicity. Rep Radiother Oncol. 2016;In Press(In Press). doi: 10.5812/rro.64853.
  • 6. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in african-americans compared with caucasians. Clin Cancer Res. 2006;12(18):5491-5. doi: 10.1158/1078-0432.CCR-06-0747. [PubMed: 17000684].
  • 7. Dong QM, He YJ, Li S, Zhou ZM, Zhang L, Zhou ZW, et al. Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients. Aizheng/Chin J Cancer. 2005;24(4):483-7.
  • 8. National Cancer Institute. Common terminology criteria for adverse events V4.0 (CTCAE). 2013, [updated 2013]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
  • 9. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004;100(3):531-7. doi: 10.1002/cncr.11925. [PubMed: 14745869].
  • 10. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19(5):447-64. doi: 10.1097/CAD.0b013e3282f945aa. [PubMed: 18418212].
  • 11. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93. doi: 10.1200/JCO.1999.17.2.485. [PubMed: 10080589].
  • 12. Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget. 2016;7(46):76298-307. doi: 10.18632/oncotarget.11818. [PubMed: 27602586]. [PubMed Central: PMC5342815].
  • 13. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-12. [PubMed: 11156223].
  • 14. Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013;10(2):89-92. [PubMed: 23603345].
  • 15. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272-5. doi: 10.1007/s00280-005-0139-8. [PubMed: 16292536].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments